Detail akcie Dare Bioscience Rg online

Business Summary: Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Dare Bioscience Inc revenues decreased 72% to $2.8M. Net loss decreased 3% to $30.2M. Revenues reflect License fee revenue decrease of 90% to $1M. Lower net loss reflects Research and development expenses decrease of 29% to $20.7M (expense), Other income increase of 78% to $778K (income), Operating lease cost decrease of less than 1% to $600K (expense).